Drug intelligence / Profile preview

1G9

Development stage: Preclinical
Modality: Antibody-Based Therapeutics

Overview

1G9 is a TIGIT blocking antibody under investigation for its potential therapeutic application in Acute Kidney Injury (AKI). It functions by inhibiting the T cell immunoreceptor with Ig and ITIM domains (TIGIT), which has been shown to increase glucose uptake and modulate the bioenergetics of kidney T cells. This metabolic reprogramming through TIGIT targeting is being explored as a novel strategy to mitigate kidney ischemia-reperfusion injury.

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on 1G9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1G9.

Explore the full profile